双基诺林聚胺结合物 (QPC):与牛血清白蛋白 (BSA) 的相互作用
Zhiyong Tian1, Tengli Ding1, Hanjing Niu1
1Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng 475004, China.
概括
一种新型的2-phenylquinoline-polyamine结合物 (QPC) 与牛血清白蛋白 (BSA) 相互作用,形成一个复合物,主要是通过疏水和结合. 谱学和计算分析显示,QPC与BSA II位点结合,导致轻微的结构变化.
科学领域:
- 生物化学 生物化学
- 化学生物学 化学生物学
- 频谱学是一种光谱学.
背景情况:
- 牛血清白蛋白 (BSA) 是生物系统中至关重要的蛋白质载体.
- 了解药物与蛋白质相互作用对于药理动力学和药物开发至关重要.
研究的目的:
- 为了合成和表征一种新的2 - 基诺林 - 聚胺合物 (QPC).
- 用各种光谱和计算技术研究QPC和BSA之间的相互作用机制.
主要方法:
- 紫外线-Vis吸收光谱法 吸收光谱法
- 光光谱学是一种光谱学.
- 循环二元化 (CD) 光谱学 循环二元化 (CD) 光谱学
- 分子对接是分子对接.
- 分子动力学模拟的模拟.
主要成果:
- QPC与BSA形成了一个复合体,由光谱变化 (UV-Vis增强,光火) 证明.
- 相互作用涉及静态和动态光火机制.
- 结合是由范德瓦尔斯力,键和疏水相互作用驱动的,QPC与BSA的II位点结合.
- 在BSA中,QPC诱导了微妙的形状变化,如同步和3D光光谱学所示.
结论:
- QPC通过非共价力的组合与BSA相互作用.
- 2-phenylquinoline部分在与BSA.的疏水相互作用中发挥着重要作用.
- 实验和理论结果之间观察到的差异可能源于化合物不稳定性.
相关概念视频
Protein-Drug Binding: Mechanism and Kinetics
661
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
661
Drug Distribution: Plasma Protein Binding
5.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.8K
Factors Affecting Protein-Drug Binding: Drug Interactions
208
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
208
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
304
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
304
Factors Affecting Protein-Drug Binding: Protein-Related Factors
203
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
203
The Equilibrium Binding Constant and Binding Strength
13.0K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.0K


